Literature DB >> 22821634

Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: systematic review and meta-analysis.

Arend F L Schinkel1, Pieter A Vriesendorp, Eric J G Sijbrands, Luc J L M Jordaens, Folkert J ten Cate, Michelle Michels.   

Abstract

BACKGROUND: Previous observational studies demonstrated that patients with hypertrophic cardiomyopathy at risk for sudden cardiac death (SCD) may benefit from implantable cardioverter defibrillator (ICD) therapy. A complete overview of outcome and complications after ICD therapy is currently not available. This study pools data from published studies on outcome and complications after ICD therapy in patients with hypertrophic cardiomyopathy. METHODS AND
RESULTS: A PubMed database search returned 27 studies on 16 cohorts reporting outcome and complications after ICD therapy in patients with hypertrophic cardiomyopathy. In case of >1 publications on a particular cohort, the publication with the largest number of patients was included in the meta-analysis. ICD interventions, complications, and mortality rates were extracted, pooled, and analyzed. There were 2190 patients (mean age, 42 years; 38% women), most of whom (83%) received an ICD for primary prevention of SCD. Risk factors for SCD were left ventricular wall thickness ≥30 mm (20%), family history of SCD (43%), nonsustained ventricular tachycardia (46%), syncope (41%), and abnormal blood pressure response (25%). During the 3.7-year follow-up, the annualized cardiac mortality rate was 0.6%, the noncardiac mortality rate was 0.4%, and the appropriate ICD intervention rate was 3.3%. The annualized inappropriate ICD intervention rate was 4.8% and the annualized ICD-related complication rate was 3.4%.
CONCLUSIONS: This meta-analysis demonstrates a low cardiac and noncardiac mortality rate after ICD therapy in patients with hypertrophic cardiomyopathy. Appropriate ICD intervention occurred at a rate of 3.3%/year, thereby, most probably, preventing SCD. Inappropriate ICD intervention and complications are not uncommon.

Entities:  

Mesh:

Year:  2012        PMID: 22821634     DOI: 10.1161/CIRCHEARTFAILURE.112.969626

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  35 in total

Review 1.  Review on sudden death risk reduction after septal reduction therapies in hypertrophic obstructive cardiomyopathy.

Authors:  Angelos G Rigopoulos; Muhammad Ali; Elena Abate; Marios Matiakis; Hannes Melnyk; Sophie Mavrogeni; Dionyssios Leftheriotis; Boris Bigalke; Michel Noutsias
Journal:  Heart Fail Rev       Date:  2019-05       Impact factor: 4.214

2.  Global longitudinal strain and left atrial volume index improve prediction of appropriate implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy patients.

Authors:  Philippe Debonnaire; Joep Thijssen; Darryl P Leong; Emer Joyce; Spyridon Katsanos; Georgette E Hoogslag; Martin J Schalij; Douwe E Atsma; Jeroen J Bax; Victoria Delgado; Nina Ajmone Marsan
Journal:  Int J Cardiovasc Imaging       Date:  2014-02-06       Impact factor: 2.357

3.  Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy.

Authors:  Martin S Maron; Ethan J Rowin; Benjamin S Wessler; Paula J Mooney; Amber Fatima; Parth Patel; Benjamin C Koethe; Mikhail Romashko; Mark S Link; Barry J Maron
Journal:  JAMA Cardiol       Date:  2019-07-01       Impact factor: 14.676

Review 4.  Implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: an updated systematic review and meta-analysis of outcomes and complications.

Authors:  Nelson Wang; Ashleigh Xie; Richard Tjahjono; David H Tian; Steven Phan; Tristan D Yan; Pietro Bajona; Kevin Phan
Journal:  Ann Cardiothorac Surg       Date:  2017-07

5.  Clinical outcomes and programming strategies of implantable cardioverter-defibrillator devices in paediatric hypertrophic cardiomyopathy: a UK National Cohort Study.

Authors:  Gabrielle Norrish; Henry Chubb; Ella Field; Karen McLeod; Maria Ilina; Georgia Spentzou; Jan Till; Piers E F Daubeney; Alan Graham Stuart; Jane Matthews; Dominic Hares; Elspeth Brown; Katie Linter; Vinay Bhole; Krishnakumar Pillai; Michael Bowes; Caroline B Jones; Orhan Uzun; Amos Wong; Arthur Yue; Shankar Sadagopan; Tara Bharucha; Norah Yap; Eric Rosenthal; Sujeev Mathur; Satish Adwani; Zdenka Reinhardt; Jasveer Mangat; Juan Pablo Kaski
Journal:  Europace       Date:  2021-03-08       Impact factor: 5.214

Review 6.  Risk stratification in hypertrophic cardiomyopathy.

Authors:  S Marrakchi; I Kammoun; E Bennour; L Laroussi; S Kachboura
Journal:  Herz       Date:  2018-04-25       Impact factor: 1.443

Review 7.  Risk Stratification in Hypertrophic Cardiomyopathy.

Authors:  Alexandros Klavdios Steriotis; Sanjay Sharma
Journal:  Eur Cardiol       Date:  2015-07

8.  Myofilament protein dynamics modulate EAD formation in human hypertrophic cardiomyopathy.

Authors:  Melanie A Zile; Natalia A Trayanova
Journal:  Prog Biophys Mol Biol       Date:  2017-06-22       Impact factor: 3.667

Review 9.  [Syncope in hypertrophic (obstructive) cardiomyopathy].

Authors:  Hubert Seggewiß; Angelika Koljaja-Batzner; Kornelia Seggewiß; Malte Meesmann
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2018-05-14

Review 10.  Management of Patients With Cardiovascular Implantable Electronic Devices in Dental, Oral, and Maxillofacial Surgery.

Authors:  James Tom
Journal:  Anesth Prog       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.